Vyvanse (Lisdexamfetamine) in Adults 65 and Older: Off-Label Use, Risks, and Clinical Considerations

Is Vyvanse FDA-Approved for Use in Adults Over 65?

Vyvanse is not FDA-approved specifically for adults over 65. The drug carries labeling for ADHD in patients aged 6 years and older, and for moderate-to-severe binge eating disorder (BED) in adults. Registration trials for both indications enrolled mostly younger adults. The FDA prescribing information notes that clinical studies did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects.

Any Vyvanse prescription written for a patient 65 or older is therefore off-label by definition, regardless of the indication.

What the FDA Label Actually Says About Older Adults

The current Vyvanse prescribing information states that lisdexamfetamine is converted to d-amphetamine by red blood cell hydrolases after absorption. Because renal clearance of d-amphetamine declines with age, the label imposes a maximum dose of 50 mg/day in patients with moderate renal impairment (eGFR 15-29 mL/min/1.73 m2) and 30 mg/day in severe impairment (eGFR <15 mL/min/1.73 m2). [1] Many adults over 65 have some degree of renal impairment even without a formal CKD diagnosis, making baseline creatinine and eGFR measurement non-negotiable before initiating therapy.

Why Older Adults Are Underrepresented in Stimulant Trials

Exclusion criteria in most ADHD registration studies screen out common geriatric comorbidities: uncontrolled hypertension, coronary artery disease, history of arrhythmia, and concurrent use of several medication classes. The result is a gap between the trial population and the patients most likely to be seen in a geriatric clinic. A 2022 systematic review in The Lancet Psychiatry noted that adults over 55 represent fewer than 2% of participants in published ADHD pharmacotherapy trials despite growing recognition of ADHD persistence into older adulthood. [2]

How Common Is ADHD in Adults Over 65, and Why Does It Go Undiagnosed?

ADHD prevalence in adults aged 65 and older is estimated at 2-3% of the population, based on self-report and structured diagnostic interview data from population studies. [3] That figure likely undercounts the true burden because many of this cohort grew up before childhood ADHD was routinely diagnosed.

Diagnostic Challenges Unique to This Age Group

Cognitive symptoms of ADHD overlap substantially with early dementia, depression, medication side effects, and normal aging. The DSM-5 requires symptom onset before age 12, which demands retrospective recall over five or more decades. Clinicians may also anchor on dementia as the default explanation for inattention, bypassing an ADHD workup entirely.

One practical marker: adults who present with a lifelong, stable pattern of inattention and impulsivity across multiple settings (work, relationships, finances) are more consistent with ADHD than with a neurodegenerative process, which typically shows progressive decline from a prior baseline. The distinction matters because the treatment pathways differ sharply.

Binge Eating Disorder in Older Adults

BED is less frequently studied in adults over 65, and Vyvanse's BED indication was established in trials where mean participant age was approximately 38 years. [4] BED does occur in older adults, but its clinical presentation and comorbid metabolic risks (type 2 diabetes, metabolic syndrome) in this group are not well-characterized. Prescribing Vyvanse for BED in a 70-year-old is a clinical judgment call unsupported by direct trial data.

Pharmacokinetics of Lisdexamfetamine in Older Adults

Lisdexamfetamine is a prodrug. After oral ingestion, intestinal and red blood cell hydrolases cleave the lysine moiety to release d-amphetamine, the pharmacologically active compound. Peak plasma concentration of d-amphetamine occurs approximately 3.8 hours after a dose of lisdexamfetamine. [1]

Renal Clearance Declines With Age

D-amphetamine is eliminated primarily via renal excretion. Urinary pH affects this: alkaline urine (common with certain antacids or diets high in citrus) traps the ionized form and reduces clearance, raising plasma levels. Acidic urine does the opposite. In older adults, renal function decreases by roughly 1% per year after age 40, meaning a 70-year-old without diagnosed CKD may still have an eGFR of 55-65 mL/min/1.73 m2. [5] This alone shifts d-amphetamine half-life meaningfully.

Protein Binding and Volume of Distribution

D-amphetamine is approximately 20% protein-bound. Older adults often have lower albumin levels, which could theoretically increase free drug fractions. Body composition also shifts with age (lower lean mass, higher fat percentage), altering volume of distribution for lipophilic compounds. These changes are not captured by the weight-based dosing strategy commonly used in younger patients.

Practical Implication: Start Lower Than You Think

Given these pharmacokinetic shifts, many geriatric pharmacologists recommend starting lisdexamfetamine at 20 mg/day (the lowest approved dose) and titrating slowly over 4-6 weeks rather than following the standard adult 4-week titration schedule. This is not in the label; it reflects clinical consensus adapted from geriatric prescribing principles. [6]

Cardiovascular Risks in Geriatric Patients on Stimulants

Cardiovascular safety is the dominant concern when prescribing any amphetamine to an older adult. The baseline rate of hypertension in U.S. Adults over 65 exceeds 70%, and coronary artery disease affects roughly 20% of this cohort. [7]

Blood Pressure and Heart Rate Effects

Across the Vyvanse adult ADHD registration trials, lisdexamfetamine produced mean increases in systolic blood pressure of approximately 2-4 mmHg and heart rate increases of 3-6 bpm compared to placebo. [1] In a healthy 30-year-old, a 3 mmHg rise in systolic pressure is clinically minor. In a 68-year-old with a resting systolic of 148 mmHg on two antihypertensives, the same increment could push blood pressure to a range that warrants immediate medication adjustment.

Arrhythmia Risk

Stimulants increase sympathomimetic tone, which can provoke or exacerbate supraventricular tachycardias, atrial fibrillation, and ventricular ectopy. Atrial fibrillation prevalence rises steeply with age, affecting approximately 9% of adults over 65 in the United States. [8] The Vyvanse label lists serious cardiovascular events including sudden death, myocardial infarction, and stroke as risks, particularly in patients with pre-existing structural heart disease or cardiomyopathy. [1]

Pre-Prescribing Cardiovascular Workup

Before initiating Vyvanse in any patient over 65, the following minimum workup is standard clinical practice:

• Resting ECG to screen for prolonged QTc, pre-excitation syndromes, or arrhythmia
• Office blood pressure and pulse (repeated at two separate visits)
• History of arrhythmia, heart failure, or coronary artery disease
• Review of all concomitant medications for additive sympathomimetic or QT-prolonging effects

This workup is not codified in the Vyvanse label specifically for geriatric patients, but aligns with American Heart Association guidance on stimulant use in patients with cardiac risk factors. [9]

Drug Interactions Especially Relevant in Older Adults

Polypharmacy is the norm in adults over 65. The average Medicare beneficiary takes five or more prescription medications. Every additional drug creates an interaction surface with lisdexamfetamine.

MAOIs: Absolute Contraindication

Selegiline (Eldepryl, Zelapar) is used in early Parkinson disease, a condition whose prevalence rises sharply after age 60. Selegiline is an irreversible MAO-B inhibitor. Combining any amphetamine with any MAOI risks hypertensive crisis and serotonin syndrome. The Vyvanse label prohibits concurrent use and requires a 14-day washout after MAOI discontinuation before starting lisdexamfetamine. [1]

Antihypertensives

D-amphetamine blunts the effect of guanethidine and may partially antagonize alpha-blockers and centrally acting antihypertensives. Patients whose blood pressure is controlled on these agents may experience destabilization after starting Vyvanse. Blood pressure should be monitored weekly for the first month of therapy.

Urinary Alkalinizers

Sodium bicarbonate, acetazolamide, and some antacids raise urinary pH and increase d-amphetamine reabsorption, raising plasma drug levels unpredictably. Clinicians should review antacid use at every visit with older patients.

Serotonergic Medications

SSRIs, SNRIs, and tramadol (commonly used for chronic pain in older adults) can interact with amphetamines to increase serotonergic activity. The combination raises serotonin syndrome risk, which in older adults may present atypically (confusion, agitation, hyperreflexia without the classic hyperthermia). [10]

Cognitive and Neuropsychiatric Risks in Older Adults

Older adults are more susceptible to CNS side effects of stimulants, including insomnia, anxiety, irritability, and psychosis. These effects partly reflect changes in catecholamine receptor density and dopamine baseline that occur with aging.

Stimulant-Induced Psychosis

Amphetamine-induced psychosis is rare at therapeutic doses in younger adults but may occur more readily in older patients with subclinical neurodegenerative changes. A 65-year-old with mild cognitive impairment (MCI) may have less dopaminergic reserve to buffer a stimulant challenge, making paranoia or hallucinations a realistic risk even at low doses.

Any new or worsening paranoia, visual hallucinations, or agitated confusion in an older adult taking lisdexamfetamine should trigger immediate dose reduction or discontinuation, and a reassessment of the underlying ADHD diagnosis.

Sleep Architecture and Insomnia

D-amphetamine significantly suppresses REM sleep and delays sleep onset. Older adults already experience reduced slow-wave sleep and more fragmented sleep architecture compared to younger cohorts. [11] Adding a stimulant risks compounding these changes. Dosing Vyvanse as early in the morning as possible (before 7 a.m. When feasible) and avoiding afternoon doses reduces, but does not eliminate, this risk.

Falls and Gait

Insomnia, dizziness on standing (orthostatic hypotension is both a stimulant effect and a geriatric comorbidity), and increased heart rate contribute to fall risk. Falls are the leading cause of injury death in adults over 65 in the United States. This risk is rarely discussed in ADHD treatment conversations but deserves explicit attention in geriatric prescribing.

The 2023 American Geriatrics Society Beers Criteria and Stimulants

The 2023 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults lists stimulants (including amphetamines) in the "use with caution" category, noting risks of anorexia, weight loss, and cardiovascular adverse effects. [6] This is not an absolute contraindication, but it signals that the prescribing clinician should document a clear risk-benefit analysis and obtain informed consent that explicitly covers the geriatric-specific risks.

The following clinical decision framework, developed by the HealthRX medical team based on Beers Criteria guidance and geriatric pharmacology principles, organizes the key questions a prescriber should answer before initiating Vyvanse in a patient over 65:

HealthRX Geriatric Vyvanse Initiation Checklist

1. Has a structured ADHD diagnostic interview confirmed symptom onset before age 12 with current functional impairment across at least two settings?
2. Have dementia, depression, thyroid disease, sleep apnea, and medication side effects been excluded as primary drivers of the presenting symptoms?
3. Is the baseline eGFR documented? If eGFR <30, is the dose capped at 30-50 mg/day per labeling?
4. Has a resting ECG been performed within the past 12 months? Is QTc <450 ms?
5. Is resting blood pressure controlled below 140/90 mmHg on current medications?
6. Is the patient free of concurrent MAOI therapy (including selegiline) with a documented 14-day washout if recently discontinued?
7. Has informed consent been obtained that includes cardiovascular risk, fall risk, sleep disruption, and the off-label nature of prescribing in this age group?
8. Is a follow-up visit scheduled within 2-4 weeks of initiation to assess blood pressure, pulse, weight, sleep, and mood?

All eight criteria should be affirmatively addressed before writing the prescription.

Evidence That Does Exist for Stimulants in Older Adults With ADHD

No completed Phase 3 RCT has enrolled adults over 65 as its primary population for lisdexamfetamine specifically. The evidence that exists comes from open-label extensions, case series, and small observational studies.

The Manor et al. Open-Label Study

A 2011 open-label pilot by Manor and colleagues enrolled 27 adults aged 50-70 with diagnosed ADHD and treated them with methylphenidate (not lisdexamfetamine) for 6 weeks. Mean ADHD Rating Scale scores dropped by approximately 30% from baseline, with a side effect profile broadly similar to younger cohorts, though blood pressure required additional management in three participants. [12] This study does not validate Vyvanse specifically, but it provides a pharmacological analogy since both drugs act on dopaminergic and noradrenergic systems.

Extrapolation from the SPD489 Adult BED Trials

The two key BED trials (SPD489-343 and SPD489-344) that supported Vyvanse FDA approval for BED enrolled adults with mean ages of 38.4 and 37.7 years, respectively. Pooled data showed that lisdexamfetamine 50-70 mg/day reduced binge eating days per week from approximately 4.7 to 0.9 over 11 weeks (P<0.001 vs. Placebo). [4] No participant was over 65 in these trials. Direct application of these findings to geriatric patients requires significant caution.

ClinicalTrials.gov Field

As of mid-2025, no registered trial specifically examines lisdexamfetamine in adults over 65. Several ongoing studies examining ADHD pharmacotherapy in adults over 50 include small subgroups of older participants, but none is powered to provide geriatric-specific efficacy or safety data.

Monitoring Protocol for Older Adults Prescribed Vyvanse

If a prescriber and patient jointly decide to proceed with lisdexamfetamine therapy after a thorough risk-benefit discussion, the monitoring schedule below reflects standard geriatric pharmacology practice adapted to stimulant-specific risks.

Initiation Phase (Weeks 1-8)

• Blood pressure and pulse at week 2 and week 4 after each dose increase
• Weight at every visit (appetite suppression and weight loss accelerate sarcopenia in older adults)
• Sleep diary or structured sleep questionnaire at week 2
• Patient and caregiver report of mood, irritability, and cognition at week 4

Maintenance Phase (Every 3 Months)

• Blood pressure, pulse, weight
• eGFR (creatinine-based) annually; more frequently if baseline eGFR <45
• ADHD or BED symptom scale to document ongoing benefit
• Medication reconciliation to catch new additions (especially serotonergic drugs, MAOIs, antacids)
• Explicit inquiry about sleep quality, falls, and chest symptoms

When to Discontinue

Stop lisdexamfetamine immediately if the patient develops: sustained blood pressure above 160/100 mmHg despite antihypertensive optimization, new-onset arrhythmia, psychotic symptoms, unexplained weight loss exceeding 5% of body weight over 3 months, or first seizure. Document the discontinuation reason and report serious adverse events to the FDA MedWatch system. [13]

Alternatives to Vyvanse in Older Adults With ADHD

Non-stimulant options carry a lower cardiovascular burden and are preferred by many geriatric specialists as first-line or adjunct treatments.

Atomoxetine (Strattera): A selective norepinephrine reuptake inhibitor approved for ADHD. It carries its own cardiovascular cautions but lacks the acute sympathomimetic surge of amphetamines. A 2017 Cochrane review found atomoxetine effective for adult ADHD (standardized mean difference 0.45, 95% CI 0.35-0.54). [14]

Guanfacine extended-release (Intuniv): An alpha-2A adrenergic agonist that can lower blood pressure as a side effect, making it potentially useful in the geriatric patient with comorbid hypertension. Evidence in older adults is limited to case reports.

Bupropion: Off-label for ADHD, with modest evidence and a lower cardiovascular risk profile than amphetamines in many older patients. Seizure threshold lowering is relevant in patients with stroke history.

Behavioral interventions including cognitive behavioral therapy adapted for ADHD (CBT-A) have shown sustained benefit in adult ADHD and carry zero pharmacological risk. A 2010 RCT by Safren et al. (N=86) found CBT-A produced significant ADHD symptom reduction (mean ADHD Rating Scale score reduction of 14.2 points vs. 7.4 for relaxation therapy, P<0.001). [15] For a 67-year-old with moderate ADHD and a history of atrial fibrillation, CBT-A may be the most appropriate first intervention.